Point72 Asset Management
SRPT icon

Point72 Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Point72 Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-207,513
Closed -$4.02M – 4455
2025
Q4 		$4.47M Buy
+207,513
New +$4.37M 0.01% 1927
2024
Q4 		– Sell
-36,855
Closed -$4.6M – 2430
2024
Q3 		$4.6M Sell
36,855
-12,058
-25% -$1.67M 0.01% 904
2024
Q2 		$7.73M Buy
+48,913
New +$6.28M 0.02% 706
2023
Q4 		– Sell
-307,343
Closed -$37.3M – 2773
2023
Q3 		$37.3M Sell
307,343
-22,026
-7% -$2.49M 0.11% 238
2023
Q2 		$37.7M Buy
329,369
+280,913
+580% +$36.2M 0.11% 226
2023
Q1 		$6.68M Sell
48,456
-655,299
-93% -$85M 0.02% 677
2022
Q4 		$91.2M Sell
703,755
-148,145
-17% -$17.2M 0.31% 71
2022
Q3 		$94.2M Buy
851,900
+426,393
+100% +$43M 0.38% 50
2022
Q2 		$31.9M Sell
425,507
-1,021,704
-71% -$75.2M 0.13% 208
2022
Q1 		$113M Buy
1,447,211
+296,002
+26% +$22.7M 0.45% 35
2021
Q4 		$104M Sell
1,151,209
-694,791
-38% -$59.4M 0.41% 38
2021
Q3 		$171M Buy
1,846,000
+1,427,400
+341% +$110M 0.75% 17
2021
Q2 		$32.5M Buy
418,600
+279,614
+201% +$21.2M 0.15% 180
2021
Q1 		$10.4M Buy
+138,986
New +$12.8M 0.05% 414
2020
Q1 		– Sell
-344,710
Closed -$44.5M – 1063
2019
Q4 		$44.5M Sell
344,710
-351,975
-51% -$35.5M 0.23% 120
2019
Q3 		$52.5M Buy
+696,685
New +$82.3M 0.32% 76
2019
Q2 		– Sell
-260,790
Closed -$31.1M – 1516
2019
Q1 		$31.1M Buy
260,790
+182,897
+235% +$23.5M 0.14% 176
2018
Q4 		$8.5M Buy
77,893
+12,123
+18% +$1.52M 0.04% 436
2018
Q3 		$10.6M Sell
65,770
-199,991
-75% -$27.3M 0.04% 450
2018
Q2 		$35.1M Buy
+265,761
New +$25.1M 0.14% 189
2018
Q1 		– Sell
-579,757
Closed -$38.7M – 1113
2017
Q4 		$32.3M Sell
579,757
-1,065,518
-65% -$56.4M 0.14% 196
2017
Q3 		$74.6M Sell
1,645,275
-380,131
-19% -$15.2M 0.33% 68
2017
Q2 		$68.3M Buy
2,025,406
+1,222,106
+152% +$39.8M 0.38% 61
2017
Q1 		$23.8M Sell
803,300
-564,299
-41% -$17.5M 0.13% 210
2016
Q4 		$37.5M Sell
1,367,599
-1,916,688
-58% -$77M 0.26% 112
2016
Q3 		$202M Buy
3,284,287
+536,687
+20% +$16.2M 1.42% 7
2016
Q2 		$52.4M Sell
2,747,600
-214,631
-7% -$3.98M 0.36% 67
2016
Q1 		$57.8M Buy
2,962,231
+586,531
+25% +$10.2M 0.44% 44
2015
Q4 		$91.7M Buy
2,375,700
+1,465,330
+161% +$47.5M 0.76% 21
2015
Q3 		$29.2M Sell
910,370
-26,230
-3% -$890K 0.23% 131
2015
Q2 		$28.5M Sell
936,600
-765,600
-45% -$15.7M 0.2% 149
2015
Q1 		$22.6M Buy
1,702,200
+150,900
+10% +$2.01M 0.15% 182
2014
Q4 		$22.4M Buy
1,551,300
+1,324,000
+582% +$22.4M 0.16% 199
2014
Q3 		$4.8M Sell
227,300
-44,800
-16% -$1.01M 0.04% 406
2014
Q2 		$8.11M Buy
+272,100
New +$8.6M 0.05% 370

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's SRPT Position: Q1 2026 in Review

Point72 Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 207,513 shares — an estimated $4.02M sold.

Point72 Asset Management first reported a position in SRPT in Q2 2014 and held it in 35 quarters. The position peaked at $202M in Q3 2016. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Point72 Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 207,513 Sarepta Therapeutics shares in Q1 2026, an estimated $4.02M.
  • Point72 Asset Management first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 35 quarters.
  • Point72 Asset Management's Sarepta Therapeutics position peaked at $202M in Q3 2016.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.